Cytek Biosciences, Inc. (CTKB) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CTKB Revenue Growth
Revenue Breakdown (FY 2025)
CTKB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CTKB Revenue Analysis (2019–2025)
As of May 9, 2026, Cytek Biosciences, Inc. (CTKB) generated trailing twelve-month (TTM) revenue of $204.2 million, reflecting solid growth of +6.5% year-over-year. The most recent quarter (Q1 2026) recorded $44.1 million in revenue, down 29.0% sequentially.
Looking at the longer-term picture, CTKB's 5-year compound annual growth rate (CAGR) stands at +16.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $201.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CTKB's business is primarily driven by Product (72%), and Service (28%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ILMN (+1.2% YoY), HOLX (+2.2% YoY), and AZTA (+1.8% YoY), CTKB has underperformed the peer group in terms of revenue growth. Compare CTKB vs ILMN →
CTKB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTKBCurrent | $204M | +6.5% | +16.8% | -20.0% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 HOLX | $4.1B | +2.2% | +1.7% | 17.4% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 BIO | $2.6B | +1.9% | +0.3% | 10.5% |
CTKB Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $201.5M | +0.5% | $104.5M | 51.8% | $-40,384,000 | -20.0% |
| 2024 | $200.5M | +3.9% | $111.1M | 55.4% | $-20,523,000 | -10.2% |
| 2023 | $193.0M | +17.7% | $109.4M | 56.7% | $-27,845,000 | -14.4% |
| 2022 | $164.0M | +28.2% | $101.0M | 61.6% | $-1,804,000 | -1.1% |
| 2021 | $128.0M | +37.8% | $79.1M | 61.9% | $9.2M | 7.2% |
| 2020 | $92.8M | +60.4% | $51.7M | 55.7% | $13.7M | 14.7% |
| 2019 | $57.9M | - | $28.7M | 49.5% | $-17,256,000 | -29.8% |
See CTKB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTKB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTKB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
Is CTKB's revenue growth accelerating or slowing?
CTKB maintains +6.5% revenue growth, in line with its 5-year CAGR of +16.8%. TTM revenue stands at $204M. Growth rate remains consistent with historical average.
What is CTKB's long-term revenue growth rate?
Cytek Biosciences, Inc.'s 5-year revenue CAGR of +16.8% reflects the sustained expansion pattern. Current YoY growth of +6.5% is near this long-term average.
How is CTKB's revenue distributed by segment?
CTKB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.